Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from 4DMedical Ltd ( (AU:4DX) ).
4DMedical Ltd has applied to the ASX for quotation of 9,070 new fully paid ordinary shares under its ticker 4DX. The securities, issued on 23 February 2026 following the exercise or conversion of existing instruments, represent a minor increase to the company’s share capital and will soon be available for trading on the exchange.
The modest size of the issuance suggests a routine capital structure adjustment rather than a major fundraising initiative. For investors, the move slightly expands the free float and may reflect ongoing utilisation of employee or investor option schemes without materially affecting ownership dynamics.
The most recent analyst rating on (AU:4DX) stock is a Sell with a A$3.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Ltd is an Australian-listed medical technology company focused on advanced respiratory imaging and analysis. Traded on the ASX under the code 4DX, it develops and commercialises software and imaging solutions aimed at improving diagnosis and management of lung diseases in healthcare markets.
Average Trading Volume: 6,390,098
Technical Sentiment Signal: Buy
Current Market Cap: A$2.06B
For an in-depth examination of 4DX stock, go to TipRanks’ Overview page.